The article compares two healthcare ETFs: PJP, which focuses on pharmaceutical companies, and IBB, which spans 243 biotechnology stocks. IBB has the lower expense ratio at 0.44% versus 0.58% for PJP, while PJP pays higher dividends, $1.13 per share over the trailing 12 months compared with $0.34 for IBB. IBB had a max drawdown of nearly 40% during the 2022 bear market and has a higher beta, indicating more volatility, though it has outperformed PJP over the past year as biotech stocks surged in 2026. PJP has been more stable and has outperformed IBB over five years, with a smaller max drawdown and lower beta. The article concludes that the right choice depends on each investor's goals and risk tolerance.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Invesco Pharmaceuticals ETF vs . iShares Biotechnology ETF : Which Is the Better Buy ?
Read the original on fool.com ↗
Keywords
ETFpharmaceuticalshealthcarebiotechnology
Open a keyword to see other news on the same topic.
Related news
- Why Healthcare ETFs Are Hovering Around One-Year Highs
Healthcare ETFs are near one-year highs, supported by an improving earnings outlook, positive trial data, relatively attractive valuations, and a shift out of crowded AI/tech trades. The State Street Health Care Select Sector SPDR ETF (XLV) rose 23.2% over six months (as of Oct. 20, 2026), versus about 9.2% for the State Street SPDR S&P 500 ETF Trust (SPY). S&P 500 healthcare companies are expected to post double-digit earnings growth from Q4 2026 through 2027, and sector M&A value has reached nearly $284 billion this year, approaching 2025's $306 billion. Notable 2026 readouts include Eli Lilly's retatrutide (28.3% average weight loss over 80 weeks at the 12-mg dose) and Vertex's povetacicept (49.8% proteinuria reduction vs. placebo at Week 36). The article also profiles the VanEck Biotech ETF (BBH, up 30.8% YTD) and Invesco Biotechnology & Genome ETF (PBE, up 20.5% YTD).
- Rapid Micro Biosystems (RPID) is Rebuilding Credibility After an Ill-Conceived Capital Raise
White Brook Capital's Q3 2026 investor letter highlights Rapid Micro Biosystems (NASDAQ:RPID), a life sciences firm providing automated microbial detection and quality control for biopharmaceutical manufacturing. The stock closed at $0.82 on October 21, 2026, with a $40.94 million market cap, down 71.86% year to date and trading in a 52-week range of $0.76 to $4.94. White Brook says the business has strengthened, margin targets have been met, and the MilliporeSigma relationship is on track. However, the share price has suffered from an ill-conceived equity issuance and concerns that more could follow. The firm believes the share price implies a more pessimistic outlook for next year's cash use than is likely.
- Stock Market Today: Dow Rises As Oil Prices Back Off; Biotech, Pharma Stocks Shine (Live Coverage)
- Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Moderna's market cap is near $90 billion, about 3.6 times BioNTech's under $25 billion, after the two traded at similar levels for nearly the first eight months of 2026. Moderna's shares have risen more than 660% year to date on Phase 3 results for its personalized mRNA cancer vaccine intismeran autogene combined with Merck's Keytruda in melanoma, while BioNTech halted a Phase 2 colorectal cancer study in August because its vaccine proved ineffective, and co-founders Uğur Şahin and Özlem Türeci plan to leave by the end of 2026. Moderna trades above 32 times sales versus BioNTech's roughly 8 times, and analysts are far more bullish on BioNTech: 11 of 15 recommend buying, compared with only 3 of 20 for Moderna, whose average price target sits 52.5% below its share price. The author agrees BioNTech is the smarter pick at current valuations, citing its cash position of roughly $18.6 billion at the end of Q2.
- Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
Ark Invest founder Cathie Wood holds $379.1 million of CRISPR Therapeutics shares and bought $1.1 million on Oct. 9 and $2.3 million on Oct. 12 through the ARK Genomic Revolution ETF, even though the stock is down more than 25% over the past year. CRISPR's only approved therapy, Casgevy, posted $76 million in Q2 revenue, up 151% year over year, but its $2.2 million list price and the 60% revenue share going to Vertex limit its economics. The company's net loss narrowed to $91.2 million from $208.5 million, and it holds $2.36 billion in cash. The article also points to CTX-310, which cut LDL cholesterol by 53% and triglycerides by 48% after 12 months in a phase 1a trial, and to a phase 2 readout for blood thinner CTX611 expected later this year.
- Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
Ark Investment Management, led by Cathie Wood, holds $220.4 million in Beam Therapeutics (BEAM) shares through its Ark ETFs, and recently bought another $2.8 million worth on Oct. 12 and 13 for the Ark Genomic Revolution (ARKG) fund. Beam develops gene-editing therapies using base editing, which changes single nucleotides without cutting both DNA strands, and its lead candidate, risto-cel, is in early trials for severe sickle cell disease. The company is far from profitable: first-half revenue was $32.2 million, up 50.5%, and loss per share was $2.09 versus $2.12 a year earlier, while $1.15 billion in cash is expected to fund operations through mid-2029. The stock is down more than 14% this year, and the article notes that the next 12 to 18 months will bring dense data readouts that could significantly lift the shares if positive.
Related markets
Latest news
- Newegg Now Offers NVIDIA RTX Spark Laptops in the U.S. and Canada
Newegg announced that NVIDIA RTX Spark laptops are now available to order in the U.S. and Canada via Newegg.com and Newegg.ca, starting with the MSI Prestige N16 Flip AI+ priced from $3,299 USD. RTX Spark combines NVIDIA AI, RTX graphics and unified memory in one Windows PC, designed to run larger AI models locally and handle creative work, development and gaming. Creators get accelerated 3D rendering and AV1 encoding, while gamers get ray tracing, DLSS and Reflex in supported games. Purchases are limited to one unit per customer, and Newegg says it will add more systems as partners bring them to market.
- Meta’s capital-raising plans expose a major weakness in the AI boom
Meta (NASDAQ:META) shares fell 7% on Thursday despite strong earnings, after the company unveiled plans to issue a new class of non-voting Class C stock. In its filing, a special committee cited an increasingly challenging environment for raising capital, pointing to recent and anticipated large raises by Alphabet, SpaceX, Anthropic and OpenAI to fund similar AI growth. Meta said it currently has sufficient capital for its needs but wants more financing flexibility going forward, with the new shares available as early as the end of 2026. The article notes Meta raised its 2026 capital expenditure forecast to $135–145 billion, while third-quarter revenue grew 26% to $64.6 billion and capex reached $34.91 billion, pushing free cash flow negative.
- The AI Bottleneck Takes Many Forms. These 7 Stocks Will Benefit.
AI growth is hitting bottlenecks in chips, memory, power, connectivity and cooling, and the Nasdaq-100 Technology Sector Index fell more than 5% in the past week. The article highlights seven companies tackling these constraints. Nvidia still faces GPU supply limits as it ramps Blackwell and Vera Rubin, while Micron, a high-bandwidth memory maker, reported fiscal fourth-quarter 2026 revenue of $54.23 billion versus $11.32 billion a year earlier. Lumentum guided to revenue of $1.225 billion to $1.275 billion for the next quarter, Coherent's data center and communications segment hit $1.615 billion, and GE Vernova reported $24.2 billion in orders. Bloom Energy's Oracle deal covers up to 2.8 gigawatts of on-site fuel cell capacity, and Vertiv supplies cooling systems, though expanding production remains a challenge.
- Same Playbook, Different Silicon: Broadcom Holds the Throne, Marvell Plays the AMD Challenger.
Broadcom and Marvell both beat AI estimates and raised guidance, but Broadcom operates at much larger scale, with AI semiconductor revenue of $16.70 billion, up 221% year over year and 56% of total revenue. Custom XPUs supplied 73% of its AI revenue, while gross margin slipped to 75% and operating margin reached 67.9%. Marvell reported $2.74 billion in revenue, up 36.5%, with data center sales at 79% of the total, and its Google deal includes a warrant for up to 7% of its shares. Broadcom guided to Q4 revenue of about $34.8 billion and AI revenue of about $21.7 billion, while Marvell guided to $3.15 billion and plans about $1 billion in supplier prepayments. Marvell is up 163.4% year to date, while Broadcom is down 6.09%.
- Arm’s Ready-Made Blueprints: The Blueprint Attack on Marvell’s Challenger Crown
Arm reported fiscal first-quarter revenue of $1.29 billion, up 22%, and says AGI CPU demand now exceeds $2 billion, though locked-in supply covers only the initial $1 billion. Marvell posted record revenue of $2.739 billion, up 37%, with data center sales at 79% of the total. The article argues Arm's ready-made compute subsystems and AGI CPU could let hyperscalers skip some custom design work that Marvell sells, and Arm may accept thinner margins, with first-generation AGI CPU gross margin expected in the high 30% range, maybe low 40s, versus Marvell's 58.9% non-GAAP gross margin. Marvell's non-GAAP operating margin rose to 36.6% from 34.8%, while Arm trades at about 248 times earnings. Over the past month, Arm fell 36.94% and Marvell lost 14.8%.
- Alphabet Solves the AI Infrastructure Bottlenecks Competitors Can’t Buy with Debt
The author argues Alphabet (NASDAQ:GOOGL) has an edge by owning its TPU chips, power, private fiber networks and multimodal training data, while rivals must rent them. Google Cloud revenue in Q2 2026 rose 82% to $24.77 billion, and operating income climbed 30.38% to $40.77 billion. The article cites a trailing P/E of 14, debt-to-equity of 0.14, and a 5% quarterly dividend increase to $0.22, and compares these with higher P/E ratios at Microsoft and Amazon. Risks noted include Q2 capital expenditures of $44.92 billion, which pushed free cash flow to -$5.86 billion, long-term debt rising to $98.2 billion, and $49.6 billion raised in equity. After the stock fell 7.16% over the week to $324.22, the author says they bought more shares.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.